Baidu
map

JAMA Oncol:间歇性与持续性雄激素阻断治疗前列腺癌疗效比较

2015-09-23 sunshine 译 MedSci原创

JAMA Oncol:间歇性与持续性雄激素阻断治疗前列腺癌疗效比较雄激素阻断疗法是治疗晚期及复发性前列腺癌的标准疗法,但是这种疗法存在很多的副作用,可降低患者的生活质量,甚至可导致去势抵抗性疾病。间断性雄激素疗法可作为一种替代疗法来加以应用。该综述回顾分析并比较了间歇性与雄激素阻断疗法治疗对前列腺癌的治疗效果。研究人员检索了截至2014年3月纳入Cochrane CENTRAL、Medline、

雄激素阻断疗法是治疗晚期及复发性前列腺癌的标准疗法,但是这种疗法存在很多的副作用,如降低患者的生活质量,甚至可导致去势抵抗性疾病。间断性雄激素疗法可作为一种替代疗法来加以应用。


该综述回顾分析并比较了间歇性与雄激素阻断疗法治疗对前列腺癌的治疗效果。

研究人员检索了截至2014年3月纳入Cochrane CENTRAL、Medline、 Embase、Web of Science、 Biosis、 National Technical Information Service、 OpenSIGLE以及Google Scholar数据库的相关指南、综述以及其他相关的文章。筛选了对比间歇性与持续性雄激素阻断疗法治疗前列腺癌患者的随机临床试验。

由两位研究人员进行了研究的筛选、 数据的提取以及风险偏倚评估。采用随机效应模型,使用倒方差法计算了风险比(HRs),使用Mantel-Haenszel法计算了相对危险度。采用非劣势分析计算了总生存率,边界为1.15,作为HR的上界。使用 I2指数评估异质性。

主要结果为总生存率及生活质量,次要结果为癌症相关生存率、无进展生存率、去势抵抗发生的时间,骨相关作用以及其他的副作用。

研究共检索了10510篇文献,最终纳入22篇于2000-2013年发表的文章,涉及15项试验,共6856名患者,其中一项研究存在原因不明或很高风险的偏倚。通过对比,研究人员发现,间歇性疗法与持续性疗法在总生存率(HR,1.02;95% CI,0.93-1.11;8项试验,5352患者)、癌症相关生存率(HR,1.02; 95% CI,0.87-1.19;5项试验,3613 名患者)以及无进展生存率(HR,0.94;95% CI,0.84-1.05;4项试验,1774名患者)上并无明显差异。此外,两组患者自我报告的生活质量水平差异极小。大部分接受间歇性治疗的患者的身体状况以及性生活情况得到了很大的改善。

总而言之,间歇性雄激素阻断疗法的患者总生存率并不低于持续性雄激素疗法。而采用间歇性疗法时,或可改善患者的某些生活质量标准。间歇性雄激素阻断疗法可作为复发性或转移性前列腺癌患者的替代疗法。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641257, encodeId=cb45164125efd, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Feb 21 06:58:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710014, encodeId=5a041e1001474, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Oct 22 03:58:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864700, encodeId=84781864e00f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 12 21:58:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954995, encodeId=5534195499576, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 28 09:58:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922531, encodeId=546c192253163, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Nov 15 18:58:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385148, encodeId=22141385148fd, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Sep 25 07:58:00 CST 2015, time=2015-09-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641257, encodeId=cb45164125efd, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Feb 21 06:58:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710014, encodeId=5a041e1001474, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Oct 22 03:58:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864700, encodeId=84781864e00f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 12 21:58:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954995, encodeId=5534195499576, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 28 09:58:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922531, encodeId=546c192253163, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Nov 15 18:58:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385148, encodeId=22141385148fd, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Sep 25 07:58:00 CST 2015, time=2015-09-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641257, encodeId=cb45164125efd, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Feb 21 06:58:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710014, encodeId=5a041e1001474, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Oct 22 03:58:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864700, encodeId=84781864e00f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 12 21:58:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954995, encodeId=5534195499576, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 28 09:58:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922531, encodeId=546c192253163, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Nov 15 18:58:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385148, encodeId=22141385148fd, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Sep 25 07:58:00 CST 2015, time=2015-09-25, status=1, ipAttribution=)]
    2016-04-12 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641257, encodeId=cb45164125efd, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Feb 21 06:58:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710014, encodeId=5a041e1001474, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Oct 22 03:58:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864700, encodeId=84781864e00f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 12 21:58:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954995, encodeId=5534195499576, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 28 09:58:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922531, encodeId=546c192253163, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Nov 15 18:58:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385148, encodeId=22141385148fd, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Sep 25 07:58:00 CST 2015, time=2015-09-25, status=1, ipAttribution=)]
    2015-09-28 仁医06
  5. [GetPortalCommentsPageByObjectIdResponse(id=1641257, encodeId=cb45164125efd, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Feb 21 06:58:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710014, encodeId=5a041e1001474, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Oct 22 03:58:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864700, encodeId=84781864e00f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 12 21:58:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954995, encodeId=5534195499576, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 28 09:58:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922531, encodeId=546c192253163, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Nov 15 18:58:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385148, encodeId=22141385148fd, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Sep 25 07:58:00 CST 2015, time=2015-09-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1641257, encodeId=cb45164125efd, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Feb 21 06:58:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710014, encodeId=5a041e1001474, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Oct 22 03:58:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864700, encodeId=84781864e00f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 12 21:58:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954995, encodeId=5534195499576, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 28 09:58:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922531, encodeId=546c192253163, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Nov 15 18:58:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385148, encodeId=22141385148fd, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Sep 25 07:58:00 CST 2015, time=2015-09-25, status=1, ipAttribution=)]

相关资讯

ASCO 2014:复发PSA患者即刻ADT 无必要

美国临床肿瘤学会(ASCO)2014年年会上发布的一项观察性研究显示,具有前列腺特异性抗原(PSA)的男性患者,接受前列腺癌治疗后复发时,即刻雄激素阻断疗法(ADT)相较于延迟ADT,并不会让患者受益。 该研究资料来源于国家癌症档案库,研究者抽取了约2000名伴有PSA复发但无癌症复发其他迹象的男性患者,他们接受即刻或延迟ADT治疗至少2年,或者治疗持续到癌症发生转移、出现疾病症状或PS

ASCO 2014:复发PSA患者即刻ADT 无必要

《期刊观察》(Journal Watch)5月16日新闻。 美国临床肿瘤学会(ASCO)2014年年会上发布的一项观察性研究显示,具有前列腺特异性抗原(PSA)的男性患者,接受前列腺癌治疗后复发时,即刻雄激素阻断疗法(ADT)相较于延迟ADT,并不会让患者受益。 该研究资料来源于国家癌症档案库,研究者抽取了约2000名伴有PSA复发但无癌症复发其他迹象的男性患者,他们接受即刻或延迟ADT治疗至

Baidu
map
Baidu
map
Baidu
map